Occupation Physician, Urologist Name Shahrokh Shariat | Residence Vienna, Austria | |
 | ||
High risk prostate cancer - which sequence of therapy should I choose?
Shahrokh François Shariat is currently professor and chairman of the department of urology, Medical University of Vienna, Vienna General Hospital, Vienna, Austria. He is also adjunct professor of urology and medical oncology at Weill Cornell Medical Center, New York, NY and adjunct professor of urology at the University of Texas Southwestern Medical Center, Dallas, TX, USA. He is currently standing visiting professor at the Charles University of Prag. He has published more than 920 peer-reviewed research papers (h-index: 80), >200 non-peer-reviewed research papers, and 18 book chapters, is the holder of four patents stemming from his research into prostate and bladder cancer, and is the recipient of various national and international rewards. He is the recipient of the prestigious Matula award from the European Urological Association in 2014 and the prestigious Gold Cystoscope award from the American Urological Association in 2017.
He is currently spearheading several collaborative multicenter groups (Bladder Cancer Research Consortium, The Bladder Cancer Detection Group, and The Upper Tract Urothelial Carcinoma Collaboration) and prospective clinical trials. He is a member of various academic societies and a journal, meeting abstract, and grant reviewer for numerous national and international organizations. He is an editorial board member of various journals including European Urology, BJU International, World Journal of Urology, Current Opinion in Urology, Immunotherapy, and Journal of Men's Health among others. His research focuses on urologic oncology - molecular mechanisms, markers, early detection, natural history, treatment, translational and outcomes research. Specially, Dr. Shariat's has been working on the discovery, testing, and validation of molecular markers associated with the biological and clinical behavior of prostate and urothelial cancers. His laboratory research focuses on integrative genomics and epigenomics of urothelial carcinoma with the goal of designing personalized therapeutic strategies.
Contents
- High risk prostate cancer which sequence of therapy should I choose
- Background
- Areas of Focus
- References
Background
Dr. Shariat was born in Tehran, Iran grew up in Vienna, Austria, attending the Lycée Français de Vienne and the Medical University of Vienna. His education also brought him to Switzerland and Spain for extended periods of time, where he developed fluency in five languages: English, French, German, Spanish and Persian. After receiving his medical degree from the University of Vienna in 1998, Dr. Shariat continued his education with postdoctoral fellowships in Gene Therapy for Urologic Diseases and Urologic Oncology at Baylor College of Medicine in Houston, before moving on to the University of Texas Southwestern Medical Center for his internship and residency followed working as a fellow and faculty instructor at Memorial Sloan-Kettering Cancer Center. He joined in 2010 the New York Presbyterian Hospital and Weill Cornell Medical Center in New York, NY.
Areas of Focus
Dr. Shahrokh Shariat specializes in treating urologic malignancies. He has published more than 920 research papers and is the holder of five patents stemming from his research into prostate cancer and bladder cancer. Dr. Shariat also reviews grant proposals for cancer research foundations and reviews paper submissions for many journals. He has been repeatedly recognized as one of the leading uro-oncologist worldwide winning many awards from diverse societies and patient self-help groups.
Dr. Shariat's research focuses on the following areas:
- Translational research in robotic prostatectomy and [prostate cancer]- molecular mechanisms, markers, early detection, natural history, treatment, translational and outcomes research
- Translational research in bladder cancer and upper tract urothelial carcinoma - molecular mechanisms, markers, early detection, natural history, treatment, translational and outcomes research
- Gene, vaccine and immuno therapies for urologic diseases with focus on bladder and prostate cancers
- Minimal invasive instrumental treatment modalities for BPH and prostate cancer.